Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 4 7Phase 2 3Phase 2/3 2Phase 3 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 117Neoplasms 101Prostatic Neoplasms 76Carcinoma, Non-Small-Cell Lung 75Colorectal Neoplasms 73Carcinoma, Hepatocellular 67Leukemia, Myeloid, Acute 58Stomach Neoplasms 52Neoplasm Metastasis 50Lung Neoplasms 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Pancreatic Neoplasms 40Recurrence 36Head and Neck Neoplasms 32Rectal Neoplasms 30Colonic Neoplasms 30Leukemia 29Multiple Myeloma 28Ovarian Neoplasms 26Lymphoma 25Squamous Cell Carcinoma of Head and Neck 24Hematologic Neoplasms 23Melanoma 22Urinary Bladder Neoplasms 20Liver Neoplasms 20Polycystic Ovary Syndrome 19Myelodysplastic Syndromes 19Lymphoma, Large B-Cell, Diffuse 19Esophageal Neoplasms 19Uterine Cervical Neoplasms 16

Interventions

Haloperidol 2Lorazepam 1Chlorpromazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × Delirium × Clear all
NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

NCT03743649 2025-12-26

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
110 enrolled

Delirium, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡